With 704,000 new cases of cancer expected per year in Brazil, the Cura Meetings event created by the Cura Project Institute reinforces the need to make society aware of the benefits of clinical research

The Cura Project Institute is holding the fourth edition of Cura Meetings, a meeting that aims to continue an important debate with representatives from different health sectors and to outline strategies to expand patients' access to research in Brazil. With the theme “Expanding the population's access to Clinical Research”, the event, online and free, is supported by the Latin American Cooperative Oncology Group (LACOG) and the ETHICS Institute - Research and Teaching.

‍

‍

The 4th Cura Meetings will take place on June 16, from 14:00 to 17:00 in São Paulo and will have a face-to-face format for guests and will be transmitted online, in order to expand the knowledge and dissemination of this very important topic. To have access to the broadcast, the public must register online and free of charge, Through the link and fill out the form. After that, registrants will receive the information to follow the event, wherever they are.

Cura Meetings is already part of the Cura Project Institute's calendar of actions, and has already brought to its discussion table multiple relevant actors involved in the scenario, such as the medical community, researchers, patient associations, the pharmaceutical industry, public authorities (Ministry of Health), the medical community, representatives of clinical research centers and CROs.

According to Fernanda Schwyter, President of the Cura Project Institute: “Cura Meetings is part of the actions to mobilize directly or indirectly to support the cause that the Cura Project Institute works on a daily basis. The expected result is society's commitment to funding studies
clinicals/academics promoting the best treatment of patients, especially cancer”.

With the presence of approximately forty authorities, doctors and members of civil society, the 4th Cura Meetings announces its preliminary schedule (subject to change). Check it out:

4TH CURA MEETINGS SCHEDULE - June 16, 2023:

14 at 14:15 - Overture
14:15 to 14:30 - 1st Conference: Health in Brazil and the World and the impact of
Clinical Research in the evolution of health systems - Dr. Nelson Teich - Doctor
Oncologist and Master in Health Economics
14:30 to 14:45 - 2nd Conference: Pharmaceutical Industry: Brazil in the context
worldwide - André Gomes - Head of Clinical Operation Bristol
14:45 to 15:00 - 3rd Conference: The challenges of academic clinical research in
Brazil  - Dr. Andreia Melo - Head of Clinical Research at INCA
15:00 to 15:15 - halftime

15:15 to 16:45 — Debate
- Confirmed debaters:

• Mrs. Fernanda Schwyter - President of the Cura Project Institute
• Mrs. Lais Bonilha - Coordinator of the National Research Ethics Committee -
  CONEP
• Mr. Claudiosvam Martins Alves de Sousa - Clinical Research Coordinator of
  National Health Surveillance Agency - ANVISA
• Dr. Gustavo Werutsky - Chair of the Latin American Cooperative Oncology Group - Lacog
• Mr. Fábio Fedozzi — Executive Director of ABRALE/TJCC
• Dr. Roberto Jun Arai - Associate Director of Astrazeneca - R&D Department
• Dr. Rodrigo Munhoz - Oncologist at Hospital Sírio Libanes
• Mr. Paulo Fernandes - Director - President of Abracro - Brazilian Association of
  Representative Clinical Research Organizations and CEO Sail for Health
• Mr. Fernando Francisco - Executive Manager of Abracro - Brazilian Association of
  Representative Clinical Research Organizations
• Dr. Analuza Bolivar Dellari - Doctor and Master in Clinical Research Law
• Dr. Heloisa Resende - Medical Oncologist/Member of the Scientific Committee of Cura
• Dr. José Márcio Barros Figueiredo - Medical Oncologist/Member of the Scientific Committee
  From Cura
• Dr. Marisa Madi — Executive Director of SBOC

16:45 to 17:00 - Final Thoughts and Closing

LEARN MORE AND SIGN UP FOR FREE

About Oncology Clinical Research

According to the 2023 Estimate on the Incidence of Cancer in Brazil released by the National Cancer Institute (INCA) of the Ministry of Health, the expectation is that there will be 704,000 new cases of cancer in Brazil per year from 2023 to 2025.

Under this scenario, scientific research is not only necessary but urgent, but to get an idea, only 2.3% of global studies are carried out in Brazil, and the average time for approval of clinical studies in the country is 215 days, much higher than countries such as Argentina (113 days), Mexico (86 days) and the United States (only 32 days). Barriers are also found for the institution
of these studies in Brazil, especially with regard to bureaucratic restrictions, multiple instances of government approval, unpredictability of the study approval schedule, restricted funding sources, lack of public interest and patient awareness.

Thus, in order for new drugs and improved protocols for cancer diagnostics, tests, and treatment to be available on the market to the population, several steps are necessary to obtain registrations for these products or procedures. This registration is only possible after the various phases of proving the efficacy and safety of the drug or procedure. This evidence is found in research trials, from basic research to clinical research, involving human beings.

To make a donation and learn more about our projects, visit our Donation tab, follow our Social Networks @projetocura or contact us at eventos@projetocura.org